Purdue Pharma Lp Drug Patent Portfolio
Purdue Pharma Lp owns 8 orange book drugs protected by 128 US patents with Chirocaine having the least patent protection, holding only 1 patent. And Hysingla Er with maximum patent protection, holding 42 patents. Given below is the list of Purdue Pharma Lp's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11857547 | Compositions and methods for opioid antagonist delivery | 05 Nov, 2039 | Active |
US11865112 | Compositions and methods for opioid antagonist delivery | 05 Nov, 2039 | Active |
US10722473 | Methods and compositions particularly for treatment of attention deficit disorder | 19 Nov, 2038 | Active |
US10111839 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10292938 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10292939 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10449159 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10500162 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10507186 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10512612 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10512613 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10568841 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US10688060 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US9974752 | Methods and compositions particularly for treatment of attention deficit disorder | 30 Oct, 2035 | Active |
US11191908 | Syringe shock absorber for use in an injection device | 18 Oct, 2035 | Active |
US11813435 | Needle assisted injection device having reduced trigger force | 25 Feb, 2035 | Active |
US10881798 | Needle assisted injection device having reduced trigger force | 11 Feb, 2034 | Active |
US8808740 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
US9572779 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
US9750703 | Encased tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
US9861584 | Tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
US9872837 | Tamper resistant controlled release dosage forms | 21 Dec, 2031 | Active |
US11185642 | Injection device with cammed ram assembly | 28 Aug, 2031 | Active |
US10357609 | Needle assisted jet injection device having reduced trigger force | 21 Aug, 2031 | Active |
US10905827 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
US11446440 | Needle assisted injection device having reduced trigger force | 21 Aug, 2031 | Active |
US8496619 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
US9364610 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
US9364611 | Needle assisted jet injection device having reduced trigger force | 21 Aug, 2031 | Active |
US9446195 | Injection device with cammed ram assembly | 21 Aug, 2031 | Active |
US10279131 | Injection device with cammed RAM assembly | 31 Jul, 2031 | Active |
US8894987 | Tamper resistant dosage forms | 29 Mar, 2030 | Active |
US11304908 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US11304909 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9084816 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9095614 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9095615 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9486412 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9486413 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9492389 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9492390 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9492391 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9545380 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9763933 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9770416 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9775809 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US11964056 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US8808741 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US8894988 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9492392 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9492393 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US9775808 | Tamper resistant dosage forms | 24 Aug, 2027 | Active |
US8021335 | Prefilled syringe jet injector | 04 Oct, 2026 | Active |
US10478560 | Prefilled syringe injector | 24 Jan, 2026 | Active |
US11446441 | Prefilled syringe injector | 24 Jan, 2026 | Active |
US8562564 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
US9180259 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
US9533102 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
US9629959 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
US7776314 | Abuse-proofed dosage system | 19 Apr, 2025 | Active |
US10407434 | Process for preparing oxycodone compositions | 30 Mar, 2025 | Active |
US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Active |
US9522919 | Oxycodone compositions | 30 Mar, 2025 | Active |
US11844865 | Abuse-proofed oral dosage form | 13 Feb, 2025 | Active |
US8114383 | Abuse-proofed dosage form | 10 Oct, 2024 | Expired |
US10130591 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
US8309060 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
US10675278 | Crush resistant delayed-release dosage forms | 20 Nov, 2023 | Expired |
US10369109 | Abuse-proofed dosage form | 16 Jun, 2023 | Expired |
US9675610 | Abuse-proofed dosage form | 16 Jun, 2023 | Expired |
US8846090 | Matrix for sustained, invariant and independent release of active compounds | 04 Apr, 2023 | Expired |
US8846091 | Matrix for sustained, invariant and independent release of active compounds | 04 Apr, 2023 | Expired |
US9555000 | Pharmaceutical preparation containing oxycodone and naloxone | 04 Apr, 2023 | Expired |
US9907793 | Pharmaceutical preparation containing oxycodone and naloxone | 04 Apr, 2023 | Expired |
US8529948 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
US8337888 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
US9060976 | Pharmaceutical formulation containing gelling agent | 06 Aug, 2022 | Expired |
US8969369 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9056051 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9084729 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9161937 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9168252 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9283216 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9283221 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9345701 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US9511066 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
US6733783 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
US8361499 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
US8551520 | Controlled release hydrocodone | 30 Oct, 2021 | Expired |
US8647667 | Controlled release hydrocodone formulations | 30 Oct, 2021 | Expired |
US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis | 09 Nov, 2020 | Expired |
US9023401 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9056052 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9060940 | Controlled release hydrocodone | 30 Oct, 2020 | Expired |
US9198863 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9205056 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9289391 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9517236 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9572804 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9669023 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9669024 | Controlled release hydrocodone formulations | 30 Oct, 2020 | Expired |
US9675611 | Methods of providing analgesia | 30 Oct, 2020 | Expired |
US9682077 | Methods of providing analgesia | 30 Oct, 2020 | Expired |
US6277384 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
US6696066 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
US8673355 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations | 22 Dec, 2018 | Expired |
US9205082 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations | 22 Dec, 2018 | Expired |
US9642850 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
USRE41408 | Method of providing sustained analgesia with buprenorpine | 29 Sep, 2017 | Expired |
USRE41489 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
USRE41571 | Method of providing sustained analgesia with buprenorphine | 29 Sep, 2017 | Expired |
US6488963 | Hot-melt extrudable pharmaceutical formulation | 24 Jun, 2017 | Expired |
US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid | 18 Dec, 2015 | Expired |
US6344211 | Transdermal absorption of active substances from subcooled melts | 18 Dec, 2015 | Expired |
US5958452 | Extruded orally administrable opioid formulations | 04 Nov, 2014 | Expired |
US5965161 | Extruded multi-particulates | 04 Nov, 2014 | Expired |
US6335033 | Melt-extrusion multiparticulates | 04 Nov, 2014 | Expired |
US6706281 | Melt-extrusion multiparticulates | 04 Nov, 2014 | Expired |
US6743442 | Melt-extruded orally administrable opioid formulations | 04 Nov, 2014 | Expired |
US5708011 | Use of levobupivacaine in a patient having depressed myocardial contractility | 13 Oct, 2014 | Expired |
US5508042 | Controlled release oxycodone compositions | 16 Apr, 2013 | Expired |
Latest Legal Activities on Purdue Pharma Lp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Purdue Pharma Lp.
Activity | Date | Patent Number |
---|---|---|
Expire Patent
Critical
| 15 Jul, 2024 | US10675278 |
Expire Patent
Critical
| 01 Jul, 2024 | US9345701 |
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US8309060 |
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US8309060 |
Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9545380 |
Electronic Review
Critical
| 07 Jun, 2024 | US11964056 |
Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9522919 (Litigated) |
Expire Patent
Critical
| 29 Apr, 2024 | US9289391 |
Email Notification
Critical
| 23 Apr, 2024 | US11964056 |
Recordation of Patent Grant Mailed
Critical
| 23 Apr, 2024 | US11964056 |
Patent Issue Date Used in PTA Calculation
Critical
| 23 Apr, 2024 | US11964056 |
Recordation of Patent eGrant | 23 Apr, 2024 | US11964056 |
Patent eGrant Notification | 23 Apr, 2024 | US11964056 |
Mail Patent eGrant Notification | 23 Apr, 2024 | US11964056 |
Expire Patent
Critical
| 22 Apr, 2024 | US9283216 |
Purdue Pharma Lp's Drug Patent Litigations
Purdue Pharma Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 11, 2016, against patent number US9060976. The petitioner Amneal Pharmaceuticals, LLC, challenged the validity of this patent, with PURDUE PHARMA L.P. as the respondent. Click below to track the latest information on how companies are challenging Purdue Pharma Lp's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US9492392 | February, 2018 |
Terminated-Settled
(21 Aug, 2018)
| Purdue Pharma L.P. | Kashiv Pharma, LLC |
US9492393 | February, 2018 |
Terminated-Settled
(21 Aug, 2018)
| Purdue Pharma L.P. | Kashiv Pharma, LLC |
US9060976 | May, 2016 |
FWD Entered
(08 Nov, 2017)
| PURDUE PHARMA L.P. | Amneal Pharmaceuticals, LLC |
Purdue Pharma Lp Drug Patents' Oppositions Filed in EPO
Purdue Pharma Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP19150366A | Sep, 2022 | Bandpay & Greuter | Granted and Under Opposition |
EP06719329A | Oct, 2019 | Bandpay & Greuter | Patent maintained as amended |
EP11177516A | Feb, 2018 | Zentiva, k.s. | Revoked |
EP11177518A | Feb, 2018 | Zentiva, k.s. | Revoked |
EP11177518A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
EP11177516A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
EP11177516A | Feb, 2018 | Intas Pharmaceuticals Ltd. | Revoked |
EP11177518A | Feb, 2018 | Intas Pharmaceuticals Ltd. | Revoked |
EP11177516A | Jan, 2018 | STADA Arzneimittel AG | Revoked |
EP11177518A | Jan, 2018 | STADA Arzneimittel AG | Revoked |
EP06706682A | Dec, 2017 | G. L. Pharma GmbH | Revoked |
EP11177516A | Nov, 2017 | G. L. Pharma GmbH | Revoked |
EP11177518A | Nov, 2017 | G. L. Pharma GmbH | Revoked |
EP11177516A | Nov, 2017 | Ethypharm | Revoked |
EP11177518A | Nov, 2017 | Ethypharm | Revoked |
EP11177520A | Aug, 2017 | Ethypharm | Revoked |
EP11177520A | Aug, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
EP11177520A | Aug, 2017 | Intas Pharmaceuticals Ltd. | Revoked |
EP11177520A | Aug, 2017 | G. L. Pharma GmbH | Revoked |
EP11177518A | Jul, 2017 | Acino Pharma AG | Revoked |
EP11177516A | Jul, 2017 | Acino Pharma AG | Revoked |
EP11177520A | Jun, 2017 | STADA Arzneimittel AG | Revoked |
EP11177516A | Jun, 2017 | KRKA, d.d., Novo mesto | Revoked |
EP11177518A | Jun, 2017 | Krka, d.d., Novo mesto | Revoked |
EP11177520A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
EP11177516A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
EP11177518A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
EP11177518A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
EP11177518A | May, 2017 | Develco Pharma Schweiz AG | Revoked |
EP11177516A | May, 2017 | Develco Pharma Schweiz AG | Revoked |
EP11177516A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
EP11177520A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
EP11177520A | Apr, 2017 | Acino Supply AG | Revoked |
EP11177520A | Apr, 2017 | KRKA, d.d., Novo mesto | Revoked |
EP11177520A | Mar, 2017 | Develco Pharma Schweiz AG | Revoked |
EP11186168A | Oct, 2016 | James Poole Limited | Opposition rejected |
EP03720424A | Mar, 2016 | KRKA, d.d., Novo mesto | Revoked |
EP03720424A | Mar, 2016 | FRKelly | Revoked |
EP03720424A | Mar, 2016 | Zentiva k.s. | Revoked |
EP03720424A | Mar, 2016 | Develco Pharma Schweiz AG | Revoked |
EP03720424A | Mar, 2016 | STADA Arzneimittel AG | Revoked |
EP03720424A | Mar, 2016 | G. L. Pharma GmbH | Revoked |
EP03720424A | Mar, 2016 | Hexal AG / Sandoz International GmbH | Revoked |
EP03720424A | Mar, 2016 | ETHYPHARM | Revoked |
EP03720424A | Feb, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
EP03720424A | Feb, 2016 | Acino Pharma AG | Revoked |
EP03720424A | Dec, 2015 | Actavis Group PTC ehf | Revoked |
EP10011792A | Oct, 2015 | Setna, Rohan P. | Granted and Under Opposition |
EP10011792A | Oct, 2015 | Hoffmann Eitle | Granted and Under Opposition |
EP10011792A | Oct, 2015 | James Poole Limited | Granted and Under Opposition |
EP10011792A | Oct, 2015 | Acino Pharma AG | Granted and Under Opposition |
EP05730345A | Dec, 2011 | Actavis group PTC ehf | Patent maintained as amended |
EP05730345A | Dec, 2011 | Acino Pharma AG | Patent maintained as amended |
EP05730345A | Dec, 2011 | Elend, Almut Susanne | Patent maintained as amended |
EP2005006983W | Oct, 2009 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
EP2005006983W | Oct, 2009 | Ypsomed AG | Patent maintained as amended |
EP03720425A | Sep, 2009 | Hexal AG | Patent maintained as amended |
EP04763833A | Mar, 2008 | Purdue Pharma LP | Opposition rejected |
EP04763834A | Dec, 2007 | Purdue Pharma LP | Opposition rejected |
Purdue Pharma Lp's Family Patents
Purdue Pharma Lp Drug List
Given below is the complete list of Purdue Pharma Lp's drugs and the patents protecting them.
1. Adhansia Xr
Adhansia Xr is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10722473 | Methods and compositions particularly for treatment of attention deficit disorder |
19 Nov, 2038
(14 years from now)
| Active |
US10111839 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10292938 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10292939 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10449159 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10500162 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10507186 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10512612 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10512613 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10568841 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US10688060 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
US9974752 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adhansia Xr's drug page
2. Butrans
Butrans is protected by 6 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9642850 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(7 years ago)
| Expired |
USRE41408 | Method of providing sustained analgesia with buprenorpine |
29 Sep, 2017
(7 years ago)
| Expired |
USRE41489 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(7 years ago)
| Expired |
USRE41571 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(7 years ago)
| Expired |
US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid |
18 Dec, 2015
(8 years ago)
| Expired |
US6344211 | Transdermal absorption of active substances from subcooled melts |
18 Dec, 2015
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Butrans's drug page
3. Chirocaine
Chirocaine is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5708011 | Use of levobupivacaine in a patient having depressed myocardial contractility |
13 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chirocaine's drug page
4. Hysingla Er
Hysingla Er is protected by 42 patents, out of which 22 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8808740 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
US9572779 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
US9750703 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
US9861584 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
US9872837 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9084816 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9095614 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9095615 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9486412 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9486413 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492390 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9545380 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9775809 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US11844865 | Abuse-proofed oral dosage form |
13 Feb, 2025
(3 months from now)
| Active |
US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(10 months ago)
| Expired |
US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(10 months ago)
| Expired |
US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
US8529948 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
US6733783 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
US8361499 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
US8551520 | Controlled release hydrocodone |
30 Oct, 2021
(2 years ago)
| Expired |
US8647667 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
US9023401 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9056052 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9060940 | Controlled release hydrocodone |
30 Oct, 2020
(3 years ago)
| Expired |
US9198863 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9205056 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9289391 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9517236 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9572804 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9669023 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9669024 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
US9675611 | Methods of providing analgesia |
30 Oct, 2020
(3 years ago)
| Expired |
US9682077 | Methods of providing analgesia |
30 Oct, 2020
(3 years ago)
| Expired |
US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hysingla Er's drug page
5. Oxycontin
Oxycontin is protected by 32 patents, out of which 10 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8894987 | Tamper resistant dosage forms |
29 Mar, 2030
(5 years from now)
| Active |
US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US11964056 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US8808741 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US8894988 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492392 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9492393 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US9775808 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
US7776314 | Abuse-proofed dosage system |
19 Apr, 2025
(6 months from now)
| Active |
US10407434 | Process for preparing oxycodone compositions |
30 Mar, 2025
(5 months from now)
| Active |
US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US9522919 | Oxycodone compositions |
30 Mar, 2025
(5 months from now)
| Active |
US8114383 | Abuse-proofed dosage form |
10 Oct, 2024
(4 days ago)
| Expired |
US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(10 months ago)
| Expired |
US10675278 | Crush resistant delayed-release dosage forms |
20 Nov, 2023
(10 months ago)
| Expired |
US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(10 months ago)
| Expired |
US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
US8337888 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
US9060976 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(7 years ago)
| Expired |
US5508042 | Controlled release oxycodone compositions |
16 Apr, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxycontin's drug page
Explore Our Curated Drug Screens
6. Palladone
Palladone is protected by 6 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(3 years ago)
| Expired |
US5958452 | Extruded orally administrable opioid formulations |
04 Nov, 2014
(9 years ago)
| Expired |
US5965161 | Extruded multi-particulates |
04 Nov, 2014
(9 years ago)
| Expired |
US6335033 | Melt-extrusion multiparticulates |
04 Nov, 2014
(9 years ago)
| Expired |
US6706281 | Melt-extrusion multiparticulates |
04 Nov, 2014
(9 years ago)
| Expired |
US6743442 | Melt-extruded orally administrable opioid formulations |
04 Nov, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Palladone's drug page
7. Targiniq
Targiniq is protected by 24 patents, out of which 19 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(5 months from now)
| Active |
US9522919 | Oxycodone compositions |
30 Mar, 2025
(5 months from now)
| Active |
US8846090 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(1 year, 6 months ago)
| Expired |
US8846091 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(1 year, 6 months ago)
| Expired |
US9555000 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(1 year, 6 months ago)
| Expired |
US9907793 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(1 year, 6 months ago)
| Expired |
US8969369 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9056051 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9084729 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9161937 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9168252 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9283216 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9283221 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9345701 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US9511066 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
US6277384 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
US6696066 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
US8673355 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(5 years ago)
| Expired |
US9205082 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Targiniq's drug page
8. Zurnai (autoinjector)
Zurnai (autoinjector) is protected by 21 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11857547 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(15 years from now)
| Active |
US11865112 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(15 years from now)
| Active |
US11191908 | Syringe shock absorber for use in an injection device |
18 Oct, 2035
(11 years from now)
| Active |
US11813435 | Needle assisted injection device having reduced trigger force |
25 Feb, 2035
(10 years from now)
| Active |
US10881798 | Needle assisted injection device having reduced trigger force |
11 Feb, 2034
(9 years from now)
| Active |
US11185642 | Injection device with cammed ram assembly |
28 Aug, 2031
(6 years from now)
| Active |
US10357609 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
US10905827 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
US11446440 | Needle assisted injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
US8496619 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
US9364610 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
US9364611 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
US9446195 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
US10279131 | Injection device with cammed RAM assembly |
31 Jul, 2031
(6 years from now)
| Active |
US8021335 | Prefilled syringe jet injector |
04 Oct, 2026
(1 year, 11 months from now)
| Active |
US10478560 | Prefilled syringe injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
US11446441 | Prefilled syringe injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
US8562564 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
US9180259 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
US9533102 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
US9629959 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurnai (autoinjector)'s drug page